Differential Effects of Selenium on Benign and Malignant Prostate Epithelial Cells: Stimulation of LNCaP Cell Growth by Noncytotoxic, Low Selenite Concentrations

Kandaş, Nur Özten; Randolph, Carla; Bosland, Maarten C.

doi:10.1080/01635580802398430

Cited by 33 publications

(22 citation statements)

References 48 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one of these studies, α-tocopherol increased the incidence of prostate cancer, similar to the results of SELECT [60]. We found that selenium at physiological concentrations increased cell proliferation in LNCaP prostate cancer cells in vitro, but inhibited proliferation at higher doses [62]. These findings can be interpreted as consistent with a postulated U-shaped dose response for selenium and cancer preventive effects [63].…”

Section: Chemopreventionsupporting

confidence: 78%

A Perspective on Prostate Carcinogenesis and Chemoprevention

et al. 2015

Self Cite

View full text Add to dashboard Cite

In this perspective, modifiable carcinogenic factors for the prostate are summarized. This is followed by a discussion of how current knowledge about causation of prostate cancer and chemoprevention of prostate cancer can be used to develop preventive strategies. Prostate cancer is a slowly developing cancer which offers opportunities for preventive interventions. Only a few randomized clinical trials of prostate cancer prevention have been completed. The SELECT study with selenium and vitamin E did not find protective effects, but in two trials with 5α-reductase inhibitors risk was reduced about 25%, showing that chemoprevention is possible and indicating that the androgen receptor is a suitable target. Besides smoking cessation and reduction of obesity, there are no known dietary or life style interventions that will have a major impact on prostate cancer risk. Inflammation of the prostate is an attractive target and aspirin may be a promising candidate agent, but has not been addressed yet in preclinical and clinical studies. Antioxidants other than selenium and vitamin E are unlikely to be very effective and data on several dietary supplements are not encouraging. More candidate agents need to be identified and tested in relevant and adequate preclinical models and Phase II trials that have predictive value for outcome of Phase III randomized studies. Doing this will require a systematic approach comparing preclinical and clinical study outcomes to determine their predictive value of preventive efficacy.

show abstract

Section: Chemopreventionsupporting

confidence: 78%

A Perspective on Prostate Carcinogenesis and Chemoprevention

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among these, selenium metabolites have been postulated to selectively promote apoptosis and inhibit proliferation of cancer cells. It has also been proposed that selenium supplementation of individuals with low selenium status may increase the expression of antioxidant selenoproteins and thereby prevents DNA damage that could lead to mutations and subsequent carcinogenesis [6–8]. …”

Section: Introductionmentioning

confidence: 99%

L-Selenomethionine Does Not Protect Against Testosterone Plus 17β-Estradiol-Induced Oxidative Stress and Preneoplastic Lesions in the Prostate of NBL Rats

Özten

Schlicht

Diamond

et al. 2014

Nutrition and Cancer

Self Cite

View full text Add to dashboard Cite

Previous animal studies examining dietary selenium effects on prostatic carcinogenesis did not show preventive benefit, including one study in a rat model involving testosterone (T) and estradiol (E2)-induced prostatic oxidative stress. Here, we examined modulation of T+E2-induced prostatic oxidative stress, dysplasia, and inflammation by L-selenomethionine at 1.5 or 3.0 mg selenium/kg in NIH-07 diet in Nbl/Crl rats treated with T+E2 for 16 weeks. Hormone treatment increased immunohistochemical staining for 8-hydroxydeoxyguanosine (8-OHdG) in the prostatic sites of T+E2-induced preneoplasia (p<0.05), but selenomethionine did not attenuate 8-OHdG staining and dysplasia in the lateral prostate. Glutathione-peroxidase activity and mRNA expression were induced by T+E2 (p<0.05–p<0.0001) but not changed by selenomethionine. Selenomethionine did not cause significant responses in expression and activity of glutathione-peroxidase and MnSOD, except for a reduction of MnSOD protein expression in the lateral prostate (p<0.01). The absence of reduction of oxidative stress and dysplasia and the minimal effects on antioxidant enzymes caused by selenomethionine are consistent with the null effects observed in selenium supplementation animal studies and clinical trials. Significant (p<0.01) opposite apoptosis/cell proliferation balance responses to selenomethionine and to T+E2 occurred in the lateral and dorsal prostate, explaining why T+E2 induces lesions selectively in the lateral lobe of NBL rats.

show abstract

“…Besides SeR, both lycopene (LY), a dietary carotenoid synthesized by plants, fruits, and microorganisms with a strong antioxidant activity, and selenium (Se), an essential trace element mainly functioning through seleno-proteins and able to promote an optimal antioxidant/oxidant balance, have been shown to exert beneficial effects in BPH (12)(13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study

et al. 2013

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI). Materials and Methods:We prospectively enrolled 168 subjects affected by LUTS due to bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, randomly assigned to 1:1 ratio to daily Profluss® (group I) for 6 months or to control group (group Ic). Second group consisted of 60 subjects, with histological diagnosis of BPH, randomly assigned to 1:1 ratio to daily Profluss® + α-blockers treatment (group II) for 3 months or to control group (group IIc). After 6 months first group underwent 24 cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation parameters and for density of T-cells (CD3, CD8), B-cells (CD20) and macrophages (CD68). Results: At follow-up there were statistical significant reductions of extension and grading of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I compared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not statistical significant. A statistically significant reduction in the density of CD20, CD3, CD68, CD8 was demonstrated in group II in respect to control IIc. Conclusions: Serenoa repens+Selenium+Lycopene may have an anti-inflammatory activity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients.

show abstract

Differential Effects of Selenium on Benign and Malignant Prostate Epithelial Cells: Stimulation of LNCaP Cell Growth by Noncytotoxic, Low Selenite Concentrations

Cited by 33 publications

References 48 publications

A Perspective on Prostate Carcinogenesis and Chemoprevention

A Perspective on Prostate Carcinogenesis and Chemoprevention

L-Selenomethionine Does Not Protect Against Testosterone Plus 17β-Estradiol-Induced Oxidative Stress and Preneoplastic Lesions in the Prostate of NBL Rats

Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study

Contact Info

Product

Resources

About